Jeffrey Thiboutot, MD, MHS, comments on the recent determination that neoadjuvant chemotherapy for early non–small cell lung cancer is associated with improved outcomes.
The effective use of neoadjuvant regimens, importantly, is reliant upon a thorough diagnosis, which requires enhanced methods of biopsy in order to perform next-generation sequencing. This in turn yields a more precise understanding of the mutations involved in a particular case of cancer and, hence, a more precise course of treatment.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Early Non–Small Cell Lung Cancer: A New Vigilance for Neoadjuvant Therapy - Medscape - Aug 09, 2022.